Udodirim N Onwubiko, David Benkeser, David P Holland, Stefan D Baral, Julia L Marcus, Kenneth H Mayer, Brian Herrick, Pranay Sinha, Allison T Chamberlain, Samuel M Jenness
{"title":"在美国同性恋和双性恋男性中,HIV PrEP开始时抑郁对持续PrEP护理参与的影响。","authors":"Udodirim N Onwubiko, David Benkeser, David P Holland, Stefan D Baral, Julia L Marcus, Kenneth H Mayer, Brian Herrick, Pranay Sinha, Allison T Chamberlain, Samuel M Jenness","doi":"10.1097/QAI.0000000000003698","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV depends on consistent use, particularly during periods of increased risk. Depression, which disproportionately affects gay, bisexual, and other men who have sex with men (GBMSM), may hinder sustained PrEP engagement. This study examines how depression impacts consistent PrEP use among GBMSM in the first 18 months after initiating oral PrEP.</p><p><strong>Methods: </strong>We analyzed electronic health records for adult GBMSM prescribed oral PrEP between January 2015 and February 2022 at three clinics in Boston, MA. Participants were followed for 18 months after initial prescriptions, tracking three outcomes: temporary prescription gaps (interruptions in received prescriptions), dropping out of current PrEP care (cessation of prescriptions) and HIV seroconversion. Associations between baseline depression diagnosis and these outcomes were estimated using subdistribution and cause-specific Cox proportional hazards regression models.</p><p><strong>Results: </strong>Among 8,077 GBMSM prescribed oral PrEP, 19% had a baseline depression diagnosis. Of these, 41% experienced gaps, 38% dropped out, and 0.4% seroconverted without a prior gap. Depression was modestly associated with higher rates of PrEP disruptions (Prescription gaps: Adjusted hazard ratio [aHR] 1.10 [95% CI: 1.00, 1.20]; Dropping out: aHR 1.16 [95% CI: 1.05, 1.28]) after adjusting for age, race/ethnicity, urbanicity, high-risk sexual behavior, poverty, and bacterial STI diagnoses. However, it did not significantly impact the cumulative incidence of PrEP interruptions.</p><p><strong>Conclusions: </strong>Although depression's impact on PrEP use was modest, integrating mental health care into PrEP programs remains essential for improving engagement and supporting sustained use among GBMSM.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.\",\"authors\":\"Udodirim N Onwubiko, David Benkeser, David P Holland, Stefan D Baral, Julia L Marcus, Kenneth H Mayer, Brian Herrick, Pranay Sinha, Allison T Chamberlain, Samuel M Jenness\",\"doi\":\"10.1097/QAI.0000000000003698\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV depends on consistent use, particularly during periods of increased risk. Depression, which disproportionately affects gay, bisexual, and other men who have sex with men (GBMSM), may hinder sustained PrEP engagement. This study examines how depression impacts consistent PrEP use among GBMSM in the first 18 months after initiating oral PrEP.</p><p><strong>Methods: </strong>We analyzed electronic health records for adult GBMSM prescribed oral PrEP between January 2015 and February 2022 at three clinics in Boston, MA. Participants were followed for 18 months after initial prescriptions, tracking three outcomes: temporary prescription gaps (interruptions in received prescriptions), dropping out of current PrEP care (cessation of prescriptions) and HIV seroconversion. Associations between baseline depression diagnosis and these outcomes were estimated using subdistribution and cause-specific Cox proportional hazards regression models.</p><p><strong>Results: </strong>Among 8,077 GBMSM prescribed oral PrEP, 19% had a baseline depression diagnosis. Of these, 41% experienced gaps, 38% dropped out, and 0.4% seroconverted without a prior gap. Depression was modestly associated with higher rates of PrEP disruptions (Prescription gaps: Adjusted hazard ratio [aHR] 1.10 [95% CI: 1.00, 1.20]; Dropping out: aHR 1.16 [95% CI: 1.05, 1.28]) after adjusting for age, race/ethnicity, urbanicity, high-risk sexual behavior, poverty, and bacterial STI diagnoses. However, it did not significantly impact the cumulative incidence of PrEP interruptions.</p><p><strong>Conclusions: </strong>Although depression's impact on PrEP use was modest, integrating mental health care into PrEP programs remains essential for improving engagement and supporting sustained use among GBMSM.</p>\",\"PeriodicalId\":14588,\"journal\":{\"name\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAI.0000000000003698\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003698","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.
Background: The effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV depends on consistent use, particularly during periods of increased risk. Depression, which disproportionately affects gay, bisexual, and other men who have sex with men (GBMSM), may hinder sustained PrEP engagement. This study examines how depression impacts consistent PrEP use among GBMSM in the first 18 months after initiating oral PrEP.
Methods: We analyzed electronic health records for adult GBMSM prescribed oral PrEP between January 2015 and February 2022 at three clinics in Boston, MA. Participants were followed for 18 months after initial prescriptions, tracking three outcomes: temporary prescription gaps (interruptions in received prescriptions), dropping out of current PrEP care (cessation of prescriptions) and HIV seroconversion. Associations between baseline depression diagnosis and these outcomes were estimated using subdistribution and cause-specific Cox proportional hazards regression models.
Results: Among 8,077 GBMSM prescribed oral PrEP, 19% had a baseline depression diagnosis. Of these, 41% experienced gaps, 38% dropped out, and 0.4% seroconverted without a prior gap. Depression was modestly associated with higher rates of PrEP disruptions (Prescription gaps: Adjusted hazard ratio [aHR] 1.10 [95% CI: 1.00, 1.20]; Dropping out: aHR 1.16 [95% CI: 1.05, 1.28]) after adjusting for age, race/ethnicity, urbanicity, high-risk sexual behavior, poverty, and bacterial STI diagnoses. However, it did not significantly impact the cumulative incidence of PrEP interruptions.
Conclusions: Although depression's impact on PrEP use was modest, integrating mental health care into PrEP programs remains essential for improving engagement and supporting sustained use among GBMSM.
期刊介绍:
JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide.
JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.